{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:18:44Z","timestamp":1790659124417,"version":"4.1.0"},"reference-count":146,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH COBRE Center of Integrated Biomedical and Bioengineering Research","award":["P20 GM113131"],"award-info":[{"award-number":["P20 GM113131"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Waldenstr\u00f6m macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenstr\u00f6m macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans involve a variety of drugs and inhibitors. This review explores avenues of tumor progression and targeted drug therapy that have been investigated in WM and related B-cell lymphomas.<\/jats:p>","DOI":"10.3390\/ijms231911145","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T21:10:05Z","timestamp":1663881005000},"page":"11145","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Waldenstr\u00f6m Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-9463","authenticated-orcid":false,"given":"Ava J.","family":"Boutilier","sequence":"first","affiliation":[{"name":"Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Huang","sequence":"additional","affiliation":[{"name":"Phillips Exeter Academy, Exeter, NH 03833, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3917-3078","authenticated-orcid":false,"given":"Sherine F.","family":"Elsawa","sequence":"additional","affiliation":[{"name":"Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4065\/mcp.2010.0304","article-title":"Diagnosis and Management of Waldenstr\u00f6m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines","volume":"85","author":"Ansell","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/leu.2013.36","article-title":"How to manage Waldenstrom\u2019s macroglobulinemia","volume":"27","author":"Buske","year":"2013","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2006.06389.x","article-title":"6q deletion in Waldenstr\u00f6m macroglobulinemia is associated with features of adverse prognosis","volume":"136","author":"Ocio","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and Management of Waldenstr\u00f6m Macroglobulinemia","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-017-0405-3","article-title":"Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): An open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3816\/CLML.2011.n.021","article-title":"High-Throughput Genomic Analysis in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"11","author":"Poulain","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_13","first-page":"649","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom\u2019s macroglobulinemia","volume":"98","author":"Lambert","year":"2012","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2008-09-178228","article-title":"microRNA expression in the biology, prognosis, and therapy of Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Roccaro","year":"2009","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Boutilier, A., and Elsawa, S. (2021). Macrophage Polarization States in the Tumor Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136995"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/annonc\/mdl109","article-title":"Mast cells in Waldenstrom\u2019s macroglobulinemia support lymphoplasmacytic cell growth through CD154\/CD40 signaling","volume":"17","author":"Tournilhac","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/bloodadvances.2018021113","article-title":"Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia","volume":"2","author":"Jalali","year":"2018","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clml.2013.02.006","article-title":"The Bone Marrow Microenvironment in Waldenstr\u00f6m Macroglobulinemia","volume":"13","author":"Agarwal","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1016\/j.clml.2013.05.023","article-title":"Novel Treatment Options for Waldenstr\u00f6m Macroglobulinemia","volume":"13","author":"Leblebjian","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1078-0432.CCR-11-0111","article-title":"Eph-B2\/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom\u2019s Macroglobulinemia","volume":"18","author":"Azab","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1182\/blood-2012-03-419440","article-title":"IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia","volume":"120","author":"Hodge","year":"2012","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.bjc.6605596","article-title":"Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration","volume":"102","author":"Sonvilla","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1349-7006.2009.01334.x","article-title":"Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer","volume":"101","author":"Miyake","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_24","first-page":"192","article-title":"Overexpression of KLF13 and FGFR3 in Oral Cancer Cells. Cytogenet","volume":"128","author":"Henson","year":"2010","journal-title":"Genome Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","article-title":"FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?","volume":"78","author":"Mertens","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.21873\/anticanres.12774","article-title":"Overexpression of FGFR3 in HPV-positive Tonsillar and Base of Tongue Cancer Is Correlated to Outcome","volume":"38","author":"Bersani","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3389\/fonc.2019.01473","article-title":"MicroRNA-99a Suppresses Breast Cancer Progression by Targeting FGFR3","volume":"9","author":"Long","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/1078-0432.CCR-10-2772","article-title":"FGFR3 Is Overexpressed Waldenstr\u00f6m Macroglobulinemia and Its Inhibition by Dovitinib Induces Apoptosis and Overcomes Stroma-Induced Proliferation","volume":"17","author":"Azab","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"Massi","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: The path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109717","DOI":"10.1016\/j.biopha.2019.109717","article-title":"CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K\/Akt\/mTOR pathway","volume":"123","author":"Si","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1182\/blood-2009-07-235747","article-title":"Dual targeting of the PI3K\/Akt\/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia","volume":"115","author":"Roccaro","year":"2010","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Trotman, L.C., Niki, M., Dotan, Z.A., Koutcher, J.A., Di Cristofano, A., Xiao, A., Khoo, A.S., Roy-Burman, P., Greenberg, N.M., and Van Dyke, T. (2003). Pten Dose Dictates Cancer Progression in the Prostate. PLoS Biol., 1.","DOI":"10.1371\/journal.pbio.0000059"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ng.556","article-title":"Subtle variations in Pten dose determine cancer susceptibility","volume":"42","author":"Alimonti","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e10576","DOI":"10.15252\/emmm.201910576","article-title":"The IL -6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma","volume":"11","author":"Hashwah","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/bloodadvances.2020003664","article-title":"Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma","volume":"5","author":"Gholiha","year":"2021","journal-title":"Blood Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1038\/s41375-019-0470-4","article-title":"Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells","volume":"33","author":"Mishra","year":"2019","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CLM.2009.n.010","article-title":"Cytokines in the Microenvironment of Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"9","author":"Elsawa","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"21524","DOI":"10.1074\/jbc.M111.234146","article-title":"GLI2 Transcription Factor Mediates Cytokine Cross-talk in the Tumor Microenvironment","volume":"286","author":"Elsawa","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V114.22.1691.1691","article-title":"Inhibition of the Jak\/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenstr\u00f6m Macroglobulinemia","volume":"114","author":"Ansell","year":"2009","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.18632\/oncotarget.26946","article-title":"Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenstr\u00f6m macroglobulinemia","volume":"10","author":"Han","year":"2019","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1158\/1078-0432.CCR-09-0718","article-title":"Src Tyrosine Kinase Regulates Adhesion and Chemotaxis in Waldenstrom Macroglobulinemia","volume":"15","author":"Ngo","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2007-09-115170","article-title":"Targeting NF-\u03baB in Waldenstrom macroglobulinemia","volume":"111","author":"Leleu","year":"2008","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/2040620711410096","article-title":"The bone marrow microenvironment in Waldenstrom macroglobulinemia","volume":"2","author":"Ghobrial","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2005-09-3552","article-title":"B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstr\u00f6m macroglobulinemia","volume":"107","author":"Elsawa","year":"2006","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1158\/1078-0432.CCR-09-1837","article-title":"Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed\/Refractory Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"16","author":"Ghobrial","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.1601490","article-title":"Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2","volume":"198","author":"Han","year":"2017","journal-title":"J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","author":"Gachard","year":"2012","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1038\/bcj.2015.36","article-title":"A novel MYD88 mutation, L265RPP, in Waldenstr\u00f6m macroglobulinemia activates the NF-\u03baB pathway to upregulate Bcl-xL expression and enhances cell survival","volume":"5","author":"Nagao","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_55","first-page":"127","article-title":"Molecular regulation and role of angiogenesis in reproduction. Taiwan","volume":"56","author":"Rizov","year":"2017","journal-title":"J. Obstet. Gynecol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.msec.2019.01.006","article-title":"Therapeutic angiogenesis: From conventional approaches to recent nanotechnology-based interventions","volume":"97","author":"Augustine","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zimta, A.-A., Baru, O., Badea, M., Buduru, S.D., and Berindan-Neagoe, I. (2019). The Role of Angiogenesis and Pro-Angiogenic Exosomes in Regenerative Dentistry. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020406"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/bs.ircmb.2016.09.007","article-title":"Immunomodulatory Activity of VEGF in Cancer","volume":"330","author":"Terme","year":"2017","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtbi.2018.09.020","article-title":"Modelling skin wound healing angiogenesis: A review","volume":"459","author":"Guerra","year":"2018","journal-title":"J. Theor. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3389\/fonc.2019.01370","article-title":"Role of Matrix Metalloproteinases in Angiogenesis and Cancer","volume":"9","author":"Arreola","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Dalal, B., Quinn, T.J., Foster, L., Lin, M., Matthews, M., and Yuhan, B. (2018). Ligand-directed tumor targeting with hybrid viral phage nanoparticles. Drug Targeting and Stimuli Sensitive Drug Delivery Systems, William Andrew Publishing.","DOI":"10.1016\/B978-0-12-813689-8.00013-6"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3389\/fonc.2019.01399","article-title":"Contribution of Angiogenesis to Inflammation and Cancer","volume":"9","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fonc.2018.00248","article-title":"Unraveling the Role of Angiogenesis in Cancer Ecosystems","volume":"8","author":"Casanovas","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yu, X., and Ye, F. (2020). Role of Angiopoietins in Development of Cancer and Neoplasia Associated with Viral Infection. Cells, 9.","DOI":"10.3390\/cells9020457"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s12094-017-1668-4","article-title":"MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor. Clin","volume":"19","author":"Wang","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3816\/CLM.2009.n.011","article-title":"Angiogenesis in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"9","author":"Terpos","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2141.2007.06609.x","article-title":"Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: The ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity","volume":"137","author":"Anagnostopoulos","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/leu.2013.24","article-title":"Hypoxia-inducible factor (HIF)-1\u03b1 suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction","volume":"27","author":"Storti","year":"2013","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/0008-5472.CAN-08-4603","article-title":"Targeting Angiogenesis via a c-Myc\/Hypoxia-Inducible Factor-1\u03b1\u2013Dependent Pathway in Multiple Myeloma","volume":"69","author":"Zhang","year":"2009","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1541-7786.MCR-14-0150","article-title":"Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenstr\u00f6m Macroglobulinemia","volume":"13","author":"Muz","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ceb.2016.06.002","article-title":"Epithelial\u2013mesenchymal transition (EMT) and metastasis: Yes, no, maybe?","volume":"43","author":"Diepenbruck","year":"2016","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cell.2008.03.011","article-title":"Eph-Ephrin Bidirectional Signaling in Physiology and Disease","volume":"133","author":"Pasquale","year":"2008","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejmech.2017.07.029","article-title":"Targeting Eph\/ephrin system in cancer therapy","volume":"142","author":"Lodola","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ydbio.2018.01.012","article-title":"Getting direction(s): The Eph\/ephrin signaling system in cell positioning","volume":"447","author":"Niethamer","year":"2019","journal-title":"Dev. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3892\/ijo.2014.2519","article-title":"Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma","volume":"45","author":"Wada","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3892\/ijo.2012.1750","article-title":"Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer","volume":"42","author":"Yamamoto","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3324\/haematol.2015.133744","article-title":"Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: Analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO)","volume":"100","author":"Simon","year":"2015","journal-title":"Haematologica"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bjh.16167","article-title":"How we manage Bing\u2013Neel syndrome","volume":"187","author":"Castillo","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.lungcan.2011.12.004","article-title":"Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma","volume":"76","author":"Ishikawa","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_81","first-page":"89","article-title":"Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Healthy. Drug Benefits"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1182\/blood-2006-11-055012","article-title":"Waldenstr\u00f6m macroglobulinemia","volume":"109","author":"Vijay","year":"2007","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton Tyrosine Kinase Inhibitors","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/path.5347","article-title":"BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers","volume":"250","author":"Lavitrano","year":"2019","journal-title":"J. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12272-019-01124-1","article-title":"Development of BTK inhibitors for the treatment of B-cell malignancies","volume":"42","author":"Kim","year":"2019","journal-title":"Arch. Pharmacal Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-3-319-91439-8_7","article-title":"Ibrutinib","volume":"Volume 212","author":"Martens","year":"2018","journal-title":"Small Molecules in Hematology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Castillo","year":"2021","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2165\/11201110-000000000-00000","article-title":"Rituximab: A Review of Its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: The ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neo.2021.02.002","article-title":"Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr\u00f6m macroglobulinemia","volume":"23","author":"Wang","year":"2021","journal-title":"Neoplasia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-134460","article-title":"Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom\u2019s Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study","volume":"136","author":"Buske","year":"2020","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","article-title":"The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: Results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Buske","year":"2008","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3816\/CLM.2009.n.016","article-title":"Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"9","author":"Ioakimidis","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary Treatment of Waldenstr\u00f6m Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstr\u00f6m macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.2009.23.6315","article-title":"Rituximab and Subcutaneous 2-Chloro-2\u2032-Deoxyadenosine Combination Treatment for Patients with Waldenstr\u00f6m Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study","volume":"28","author":"Laszlo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.15718","article-title":"Bendamustine plus rituximab in newly-diagnosed Waldenstr\u00f6m macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)","volume":"186","author":"Laribi","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/hematology.2020000121","article-title":"Management of Waldenstr\u00f6m macroglobulinemia in Hematology in 2020","volume":"2020","author":"Castillo","year":"2020","journal-title":"Hematology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1111\/cas.14561","article-title":"A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"111","author":"Sekiguchi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2019-126286","article-title":"Ongoing Results of a Phase 1B\/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton\u2019S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies","volume":"134","author":"Allan","year":"2019","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/17474086.2014.871494","article-title":"Waldenstr\u00f6m macroglobulinemia: From biology to treatment","volume":"7","author":"Sahin","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/10428194.2016.1222380","article-title":"Idelalisib in Waldenstr\u00f6m macroglobulinemia: High incidence of hepatotoxicity","volume":"58","author":"Castillo","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: A practical approach","volume":"102","author":"Koopmans","year":"2017","journal-title":"Haematologica"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ajh.23814","article-title":"Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib","volume":"89","author":"Sahin","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","article-title":"Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells","volume":"107","author":"Hideshima","year":"2006","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00001813-200302000-00011","article-title":"Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase\u2013Akt\/PKB survival pathway","volume":"14","author":"Ruiter","year":"2003","journal-title":"Anti-Cancer Drugs"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1182\/blood-2007-05-092098","article-title":"The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia","volume":"110","author":"Leleu","year":"2007","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.24.0994","article-title":"Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstr\u00f6m Macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt","volume":"66","author":"Rojo","year":"2006","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Feldman, M.E., Apsel, B., Uotila, A., Loewith, R., Knight, Z.A., Ruggero, D., and Shokat, K.M. (2009). Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2. PLoS Biol., 7.","DOI":"10.1371\/journal.pbio.1000038"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/1535-7163.MCT-10-0905","article-title":"Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors","volume":"10","author":"Vilar","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbapap.2009.12.001","article-title":"Dissecting the role of mTOR: Lessons from mTOR inhibitors","volume":"1804","author":"Dowling","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Proteins Proteom."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.1158\/1078-0432.CCR-06-1331","article-title":"Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma","volume":"12","author":"Francis","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORCJ","volume":"284","author":"Thoreen","year":"2009","journal-title":"Biol. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1182\/blood-2010-05-285726","article-title":"Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor","volume":"116","author":"Hoang","year":"2010","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/CCO.0b013e32835de8ee","article-title":"Temsirolimus in the treatment of mantle cell lymphoma","volume":"25","author":"Bouabdallah","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1158\/1078-0432.CCR-12-1532","article-title":"Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia","volume":"18","author":"Roccaro","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/1078-0432.CCR-16-1918","article-title":"Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)","volume":"23","author":"Treon","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.23620","article-title":"Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia","volume":"89","author":"Ghobrial","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10549-012-2298-8","article-title":"Investigational drug MLN0128, a novel TORC1\/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models","volume":"136","author":"Liu","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2012.276","article-title":"Efficacy of the investigational mTOR kinase inhibitor MLN0128\/INK128 in models of B-cell acute lymphoblastic leukemia","volume":"27","author":"Janes","year":"2012","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.24300","article-title":"TAK-228 (formerly MLN0128), an investigational oral dual TORC1\/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"91","author":"Ghobrial","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood-2006-08-042747","article-title":"Targeting PKC in multiple myeloma: In vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)","volume":"109","author":"Podar","year":"2006","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00280-003-0713-x","article-title":"LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice","volume":"53","author":"Keyes","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1182\/blood-2006-10-054577","article-title":"Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstr\u00f6m macroglobulinemia","volume":"109","author":"Moreau","year":"2007","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12048","article-title":"Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies","volume":"76","author":"Baluom","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-020-0277-6","article-title":"SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas","volume":"10","author":"Munshi","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-14-1462","article-title":"Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenstr\u00f6m Macroglobulinemia","volume":"21","author":"Kuiatse","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_133","first-page":"6408","article-title":"Targeting Myddosome Signaling in Waldenstr\u00f6m\u2019s Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1\/4 Inhibitor RClin","volume":"24","author":"Ni","year":"2018","journal-title":"Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2014-03-559963","article-title":"The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma","volume":"124","author":"Spencer","year":"2014","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/emmm.200900028","article-title":"Onco-miR-155 targets SHIP1 to promote TNF\u03b1-dependent growth of B cell lymphomas","volume":"1","author":"Pedersen","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1073\/pnas.0500613102","article-title":"Accumulation of miR-155 and BIC RNA in human B cell lymphomas","volume":"102","author":"Eis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/43466","article-title":"NF-\u03baB activation by tumour necrosis factor requires the Akt serine\u2013threonine kinase","volume":"401","author":"Ozes","year":"1999","journal-title":"Nature"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/43474","article-title":"NF-\u03baB is a target of AKT in anti-apoptotic PDGF signalling","volume":"401","author":"Romashkova","year":"1999","journal-title":"Nature"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.4049\/jimmunol.178.4.2507","article-title":"Simvastatin Potentiates TNF-\u03b1-Induced Apoptosis through the Down-Regulation of NF-\u03baB-Dependent Antiapoptotic Gene Products: Role of I\u03baB\u03b1 Kinase and TGF-\u03b2-Activated Kinase-1","volume":"178","author":"Ahn","year":"2007","journal-title":"J. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1365-2141.2008.07257.x","article-title":"The HMG-CoA inhibitor, simvastatin, triggersin vitroanti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia","volume":"142","author":"Moreau","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2141.2005.05393.x","article-title":"Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma","volume":"128","author":"Pedersen","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Artemaki, P., Letsos, P., Zoupa, I., Katsaraki, K., Karousi, P., Papageorgiou, S., Pappa, V., Scorilas, A., and Kontos, C. (2021). The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040333"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1038\/bcj.2015.106","article-title":"miR-23b\/SP1\/c-myc forms a feed-forward loop supporting multiple myeloma cell growth","volume":"6","author":"Fulciniti","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-08-3701","article-title":"Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-\u03baB Signaling Pathways in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"69","author":"Braggio","year":"2009","journal-title":"Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1182\/blood-2010-01-265686","article-title":"microRNA-dependent modulation of histone acetylation in Waldenstr\u00f6m macroglobulinemia","volume":"116","author":"Roccaro","year":"2010","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Sanz, R., and Jim\u00e9nez, C. (2021). Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenstr\u00f6m\u2019s Macroglobulinemia\u2014A Particularly Heterogeneous Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13071541"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11145\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:37:22Z","timestamp":1760143042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":146,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms231911145"],"URL":"https:\/\/doi.org\/10.3390\/ijms231911145","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}